Please assess the completion status of the following clinical trial:

Trial Title: PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18-80 years~* Underlying pancreatic adenocarcinoma, unresectable (local invasion or distant metastasis)~* On established chemotherapy regimen for pancreas cancer, which will be continued over the time of study~* Fecal elastase-1 test (FE1) less than 200 mcg pancreatic elastase/g stool~Exclusion Criteria:~* Common bile duct obstruction resulting in obstructive jaundice~* Celiac disease~* Crohn's disease~* Benign pancreatic conditions~* Bowel obstruction~* Surgically altered bowel anatomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo First, then Pancrelipase (Type: EXPERIMENTAL): Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
- Pancrelipase First, then Placebo (Type: EXPERIMENTAL): Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).

Based on this trial design, predict the completion outcome and termination type (if applicable).